Email Alert | RSS    帮助

中国防痨杂志 ›› 2021, Vol. 43 ›› Issue (9): 965-969.doi: 10.3969/j.issn.1000-6621.2021.09.018

• 综述 • 上一篇    下一篇


祁雪婷, 陆宇(), 陈效友()   

  1. 101149 首都医科大学附属北京胸科医院 耐药结核病研究北京市重点实验室 北京市结核病胸部肿瘤研究所药物研究室(祁雪婷、陆宇);首都医科大学附属北京地坛医院(陈效友)
  • 收稿日期:2021-04-15 出版日期:2021-09-10 发布日期:2021-09-07
  • 通信作者: 陆宇,陈效友;
  • 基金资助:

Pharmacodynamic characteristics and interaction of new antituberculosis drugs

QI Xue-ting, LU Yu(), CHEN Xiao-you()   

  1. *Beijing Key Laboratory of Drug Resistance Tuberculosis Research, Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumour Research Institute, Beijing 101149, China
  • Received:2021-04-15 Online:2021-09-10 Published:2021-09-07
  • Contact: LU Yu,CHEN Xiao-you;



关键词: 分枝杆菌,结核, 抗结核药, 药物疗法,联合, 综述文献(主题)


Treatment of tuberculosis currently still relies on chemotherapy,however,there are multitude problems in the existing chemotherapy regimens, such as long treatment course, various adverse reactions, and suboptimal outcomes.There is an urgent need to exploit potent drug combinations to improve the treatment efficacy and shorten the course of treatment.Herein, the pharmacodynamic characteristics and interactions of novel anti-tuberculosis drugs launched in recent years,as well as those in the research stage, are briefly reviewed to provide reference for the research and development of anti-tuberculosis drugs and new drug combination regimens.

Key words: Mycobacterium tuberculosis, Auti-tuberculosis drugs, Drug therapy,combination, Review literature as topic